Watch on StartUp Health TV
Summary
StartUp Health community member Chris Mirro, Chief Growth Officer of Veravas, shares how the team is empowering patients and providers with the early detection of Alzheimer’s disease and other tauopathies. After a breakthrough 2025, Veravas is looking to deepen strategic partnerships to bring its Verabind tau test to more people.
Key Moments
🔬 The need: Verabind tau is the only blood test that measures active tau pathology, a key marker of Alzheimer’s, and it can detect disease before clinical symptoms appear.
🚀 The launch: In May 2025, Veravas launched the test as a laboratory developed test, a major milestone for the team.
📊 The proof: At AAIC, Veravas and a research collaborator presented 96% agreement with tau PET, kicking off the global recognition the company needed.
🤝 The community: Chris says connecting with peers, facing similar challenges, and accessing experts in the Alzheimer’s & Brain Health Moonshot Community strengthened Veravas’ capabilities and broadened its network.
🎯 The ask: Veravas is seeking introductions to clinical trial and diagnostic leaders at pharmaceutical companies. If you can help, join them in the community.
Are you ready to tell YOUR story?
Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, journal, and YouTube channel – is available to StartUp Health Members. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
🚀 Learn more and join today
